It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to reduce costs and shorten the time it ...

Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...

The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was ...

State-of-the-art AI programs can support the development of drugs by predicting how proteins interact with small molecules.

If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...

The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...

Thomson, North America business development lead for healthcare and life sciences at NVIDIA, discusses how generative, ...

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about ...

The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States.The agency issued draft guidance that would simplify the study ...

Jo Varshney, PhD, DVM, discusses how artificial intelligence–powered simulations speed drug approvals and reduce clinical ...

WuXi AppTec, a global contract research, development, and manufacturing organization (CRDMO), recently hosted its 2025 ...